- Previous Close
12.68 - Open
0.00 - Bid 12.96 x --
- Ask 13.33 x --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 24.84 - Volume
0 - Avg. Volume
9 - Market Cap (intraday)
1.089B - Beta (5Y Monthly) -0.25
- PE Ratio (TTM)
-- - EPS (TTM)
-0.08 - Earnings Date Nov 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date May 10, 2019
- 1y Target Est
--
BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
www.bioarctic.seRecent News: B9A.F
View MorePerformance Overview: B9A.F
Trailing total returns as of 11/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: B9A.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: B9A.F
View MoreValuation Measures
Market Cap
1.11B
Enterprise Value
1.07B
Trailing P/E
--
Forward P/E
303.03
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
43.80
Price/Book (mrq)
14.14
Enterprise Value/Revenue
41.84
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-29.49%
Return on Assets (ttm)
-5.24%
Return on Equity (ttm)
-9.18%
Revenue (ttm)
299.35M
Net Income Avi to Common (ttm)
-88.28M
Diluted EPS (ttm)
-0.08
Balance Sheet and Cash Flow
Total Cash (mrq)
489.68M
Total Debt/Equity (mrq)
6.42%
Levered Free Cash Flow (ttm)
-524.86M